Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase NA 10Phase 3 7Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 4Recruiting 3Withdrawn 2Terminated 2Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Surgical Procedures, Operative × Clear all
NCT05144100 2021-12-03

SCOPE

Tata Memorial Centre

Phase 2/3 Not yet recruiting
498 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡